Epinex Diagnostics Inc.
|Title:||President & CEO|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||Epinex is a biomedical device company that is developing rapid diagnostic tests targeted to markets such as diabetes, rheumatoid arthritis, Down syndrome, and neo-natal HIV testing. The Company’s initial product to be offered is the Epinex G1A™ Rapid Diabetes Monitoring Index Test (the “G1A™ test”), a patent-pending rapid test to monitor Type 2 diabetes and gestational diabetes. The Epinex G1A™ test is a monthly index test to monitor serum protein “glycation.” Glycation, the process whereby excess glucose in the blood adheres to proteins such as albumin, is an indicator of diabetes complications. The Company believes that the G1A™ test has the potential to become a monthly rapid test that can help prevent the long-term complications caused by diabetes. Scientific studies already support that glycated proteins are linked to diabetes-related complications such as blindness, kidney failure, neuropathy, heart disease. With the G1A™ test, the Company believes it will have created a new tool that promises to play a major role in a global strategy to deal with diabetes-related diseases. The Company anticipates commencing U.S. FDA registration and clinical trials and plans to apply for regulatory approval under the 510(k) protocol.|